Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

Part of paid clinical trials in Saint Augustine, Florida.

Sponsor
Verrica Pharmaceuticals Inc.
Study ID
NCT07246590
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Common Warts
  • Common Warts (Verruca Vulgaris)
  • Human Papilloma Virus (HPV)
  • Warts

Eligibility Criteria

Sex
ALL
Age
2 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • VP-102 — COMBINATION_PRODUCT
    A single-use applicator and applied in sufficient quantity to cover the entirety of each treatable common wart, including approximately a 1 to 2 mm margin of surrounding, healthy skin. The contents of no more than 2 applicators may be applied at each treatment visit. Each applicator contains 0.45 mL of 0.7% w/v cantharidin. Occlusive tape (occlusive tape with similar properties should be used across all clinical sites) will be applied to warts that have been treated. Once applied, the occlusive tape should be gently rubbed to maximize adherence to the treated area.
  • Vehicle — COMBINATION_PRODUCT
    Vehicle is contained in a single-use applicator and applied in sufficient quantity to cover the entirety of each treatable common wart, including approximately a 1 to 2 mm margin of surrounding, healthy skin. The contents of no more than 2 applicators may be applied at each treatment visit. The Vehicle applicator contains the same excipient formulation as the VP-102 applicator but does not contain the active pharmaceutical ingredient cantharidin. Occlusive tape (occlusive tape with similar properties should be used across all clinical sites) will be applied to warts that have been treated. Once applied, the occlusive tape should be gently rubbed to maximize adherence to the treated area.

Study Details

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.

Key Dates

Start date
Dec 17, 2025
Status verified
Jan 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
300 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: VP-102
    Topical solution, which is a light violet to dark purple, slightly viscous liquid. 0.7% (each mL contains 7 mg of cantharidin)/glass ampule within an applicator. Each applicator contains 0.45 mL of 0.7% w/v cantharidin. Administered Topical/every 21 (± 4) days. All treatments will take place within a 75-day period.
  • Placebo Comparator: Vehicle
    Topical solution, which is a light violet to dark purple, slightly viscous liquid. No active drug/glass ampule within an applicator. Each applicator contains 0.45 mL of 0.7% w/v cantharidin. Administered Topical/every 21 (± 4) days. All treatments will take place within a 75-day period.

Primary Outcome Measure

Proportion of subjects achieving complete clearance of all treatable common warts (baseline and new) at the Day 84 (EOT) Visit. [ Time Frame: Day 84(0/+8 days) ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
Florida Center for Dermatology, P.A.Saint AugustineFlorida32080-
The Indiana Clinical Trials Center, PCPlainfieldIndiana46168-
Anne Arundel Dermatology, PA dba Maryland Dermatology Laser Skin & VeinHunt ValleyMaryland31030-
Tennessee Clinical Research Center, Inc.NashvilleTennessee37215-
The University of Texas Health Science Center at HoustonHoustonTexas77030-
Texas Dermatology and Laser SpecialistsSan AntonioTexas78218-

Find similar trials in Saint Augustine, FL

By research site
Florida Center for Dermatology, P.A.· Saint Augustine, FLThe Indiana Clinical Trials Center, PC· Plainfield, INAnne Arundel Dermatology, PA dba Maryland Dermatology Laser Skin & Vein· Hunt Valley, MDTennessee Clinical Research Center, Inc.· Nashville, TNThe University of Texas Health Science Center at Houston· Houston, TXTexas Dermatology and Laser Specialists· San Antonio, TX

Related Studies